Eli Lilly Expands Oncology Strategy with High-Stakes Bet on Next-Generation Cell Therapies
Eli Lilly is intensifying its push into advanced cancer treatments through a major acquisition that underscores a broader strategic shift within the pharmaceutical industry. The agreement to acquire Kelonia Therapeutics for up to $7 billion reflects a calculated effort to strengthen its oncology pipeline while reducing dependence on its highly successful but increasingly competitive obesity…









